Aleix Prat
A5089513581- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Cancer Research and Treatments
- Nutrition, Genetics, and Disease
- PI3K/AKT/mTOR signaling in cancer
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Prostate Cancer Treatment and Research
- Gene expression and cancer classification
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- Computational Drug Discovery Methods
- Esophageal Cancer Research and Treatment
- Cancer-related Molecular Pathways
- Ferroptosis and cancer prognosis
Hospital Clínic de Barcelona
2016-2025
Universitat de Barcelona
2016-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2016-2025
Solti
2020-2025
Oryzon Genomics (Spain)
2022-2025
Hospital Quirónsalud Barcelona
2021-2025
Breast Cancer Research Foundation
2016-2024
Target (United States)
2016-2024
Biomedical Research Institute
2016-2024
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
2024
We analysed primary breast cancers by genomic DNA copy number arrays, methylation, exome sequencing, messenger RNA microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes demonstrated the existence of four main cancer classes when combining data from five platforms, each which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA...
Abstract Introduction In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic prognostic features. Here, we comprehensively characterize the recently identified claudin-low subtype. Methods The clinical, pathological biological features tumors were compared to other using an updated human database multiple independent data sets. These main also evaluated in a panel cancer...
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years 5-year only ∼25% [2.Cardoso Spence D. Mertz S. et al.Global analysis...
To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes. Structural and copy number aberrations were found to be retained high fidelity. However, at single-nucleotide level, variable numbers PDX-specific somatic events documented, although they only rarely functionally significant. Variant allele frequencies often preserved in PDXs, demonstrating that clonal...
PARP inhibitors are active in tumors with defects DNA homologous recombination (HR) due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway preserves HR steady state. We hypothesized that BRCA-proficient triple-negative breast cancer (TNBC), PI3K inhibition would result impairment and subsequent sensitization inhibitors. show TNBC cells leads damage, downregulation of BRCA1/2, gain poly-ADP-ribosylation, inhibition. In patient-derived primary tumor xenografts, dual...
Purpose Current immunohistochemical (IHC)-based definitions of luminal A and B breast cancers are imperfect when compared with multigene expression-based assays. In this study, we sought to improve the IHC subtyping by examining pathologic gene expression characteristics genomically defined subtypes. Patients Methods Gene features were collected from primary tumors across five independent cohorts: British Columbia Cancer Agency (BCCA) tamoxifen-treated only, Grupo Español de Investigación en...
Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed select agents III investigations.Three hundred seventy-seven postmenopausal women with clinical stage ER-positive (Allred score 6-8) cancer randomly assigned receive exemestane, letrozole, or anastrozole. The primary end point was response....
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical molecular features HER2-low BC yet to be elucidated. Here, we collected retrospective clinicopathological PAM50 data from 3,689 patients disease made following observations. First, proportion was higher HR-positive (65.4%) than triple-negative (TNBC, 36.6%). Second, within disease, luminal-related...
Abstract Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, the lack of vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort tumors grown epithelium-free mammary fat pad severe combined immunodeficient (SCID)/Beige nonobese diabetic (NOD)/SCID/IL-2γ-receptor null (NSG) mice under series transplant conditions. Both yielded stably transplantable xenografts at...
Inhibition of the PI3K/AKT pathway results in induction ER-dependent transcriptional activity and susceptibility to anti-estrogen therapy ER-positive breast cancer.
Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a variety solid tumors, but most patients exhibit partial or complete resistance to treatment for reasons that are unclear. In this study, we evaluated tumor specimens from 65 with melanoma, lung nonsquamous, squamous cell head and neck cancers who were treated approved PD1-targeting antibodies pembrolizumab nivolumab. Tumor RNA before anti-PD1 therapy was analyzed on nCounter system using PanCancer...
Abstract Summary: Breast cancer is one of the most frequent cancers among women. Extensive studies into molecular heterogeneity breast have produced a plethora subtype classification and prognosis prediction algorithms, as well numerous gene expression signatures. However, reimplementation these algorithms tedious but important task to enable comparison existing signatures models between each other with new models. Here, we present genefu R/Bioconductor package, multi-tiered compendium...
Many methodologies have been used in research to identify the "intrinsic" subtypes of breast cancer commonly known as Luminal A, B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often for expression-based subtyping; however, surrogate subtyping using panels immunohistochemical (IHC) markers are still widely clinically. Discrepancies between these methods may lead different treatment decisions.We RT-qPCR assay expression profile 814 tumors from GEICAM/9906 phase III clinical...
Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant cells chronic exposure to treatment. Genomewide copy-number variation analyses the resistant compared parental revealed a focal amplification genomic DNA containing cyclin E gene. In cohort 34 + treated trastuzumab-based therapy, found that...